A Look Inside MS Marketplace Projections

A Look Inside MS Marketplace Projections

Do you ever stop and ponder the value of MS drugs? I’m not talking about if they work and the ways they improve our lives. I’m thinking of the COST of them and what their pricing means to investors. I get several market analysis reports on the pharmaceutical industry, and one that came to my email inbox in late August had some staggering figures I’ve tried to digest and share here.

Credence Research announces on its website in bold letters that it will Find future forecasts and research analysis of important industry trends, market size, market share and company profiles of the leading industry players.”  In other words, as it relates to multiple sclerosis, it looked at overall disease modifying therapy sales, the companies that sell these drugs, and forecast growth in the MS market for investors to make better decisions.

I don’t have a spare $4,325 sitting around to purchase the full report, which is the list price. I have to rely on gleaning details from its preliminary press release and some research on the web. But even this brief summary has enough information to cause me to pause and think long and hard about the cost of MS therapies and their sales worldwide.

Projected growth rate

Let me share a few of the staggering numbers with you. In its report, “Multiple Sclerosis Drugs Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025,” Credence Research states the worldwide MS drug market had a value of $16.13 BILLON in 2016. The research predicts that, with a compound annual growth rate of 6.3 percent, the MS market will be $27.35 BILLION by 2025.

To better understand this figure, the cost for treatment of diabetes worldwide is $825 billion, but that is to treat more than 440 million people. The number of people with MS worldwide is estimated at 2.3 million. That would make the average cost for diabetes treatment about $1,875, while the average per-person cost for MS is $7,013, or more than 75 percent more. Remember, not all people are on treatment for either disease.

Other differences

The research notes differences in the MS therapies and separates them into biologics and small-molecule therapies. The company’s prediction is that small-molecule therapies will be the fastest-growing segment of the MS drug market, even though biologic-derived drugs ― interferons and Tysabri (natalizumab) ― now dominate the market. We should hear more research results on new or potential MS treatments at the upcoming European Committee for Treatment and Research in MS meeting, Oct. 25-28 in Paris.

The report also mentions that of the two ways to administer drugs, the non-oral parenteral route (injections, infusions) still dominates the market, although there are a growing number of oral drugs now available. I was somewhat surprised to read this, because I know many people who are anxious to stop injectable therapy.

US leads MS therapy use

There are other factors that are noted when researchers consider sales forecasts of disease modifying therapies, including the rising rate of MS and the larger number of people worldwide who could potentially become users of one of these drugs. For now, the U.S. market is the primary consumer and payer for these essential treatments.

On the down side, the report mentions that the MS market could drop if a drug causes serious side effects. It doesn’t mention what a real cure would do to this lucrative marketplace. I’m not one to engage in the conspiracy theory that the pharmaceutical industry has a motive to keep people with MS sick, but the bottom line for this report seems to be that MS therapies make money, they will continue to make even more money, and there is no hint that a cure may be close at hand.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

10 comments

    • Scott says:

      You are exactly right. it’s not hard to see that there is no incentive for a one time fix. Even if that one time fix cost $200,000 the majority of that cost does not go to pharmaceutical. There’s just no way around it, there’s $1 million price tag on your four head if you have MS.

  1. Alma Wardlow says:

    Oh my word it’s scary to think that there are people out there getting rich through our condition. Maybe CBD will
    Put a dent in there Finances !

    • Scott says:

      If you have MS you are worth at least $1 million to the pharmaceutical company. They have no incentive otherwise.
      I’ve been wanting to try CBD oil. Apparently it’s hard to tell what’s real and what’s not real in this market. What are your suggestions if you don’t mind? Thank you, Scott

  2. Eric Woodard says:

    All this says to me is they are not going to find a cure no time soon the profits are to high. Meanwhile people with MS continue to get worse is their anything that we can do to help ourselves like put a fund together from people with Ms and get our own researchers to find a cure or to look into treatments that are already out there we will have to do something because it doesn’t seem as if the government is going to do anything

  3. Scott Brown says:

    The answer to all of your questions is – money. Big pharma will never bring any cures to fruition as long as they make that much money….

  4. charles says:

    a new therapy based on forcing tolerance to myelin antigens would be a great thing to have. there are studies ongoing, but they are early in development. i doubt that pharmaceutical companies would support the development of a drug that has to be taken only once, and then the disease is no more. it is far more profitable to sell doses of a drug that keeps the disease pretty much under control, but only if you deep taking the drug regularly for your whole life. personally i would rather have a cure.

  5. Teresa says:

    My thoughts exactly! After 30 years with ms my doctor put me back to one of the A,B, C drugs; Copaxone.
    Also incidentally one of the cheapest on the market. My sister with ms for 10 years switched recently to Rebif from Avonex. Some doctors are analyzing the cost and effectiveness of the existing drugs vs. the shiny and new but outrageously expensive therapies. Are they really worth it.

Leave a Comment

Your email address will not be published. Required fields are marked *